The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Synonyms :
Class :
Prophylactic Measures Before Exposure:
First series: intramuscular 0.5 mL at 0, 1, and 6 months
0.5 mL intramuscularly, six and twelve months after the initial series, and then every twelve months after that is the booster series
Pre-exposure prophylaxis for individuals at risk of intramuscular injection hematomas:
Primary series: subcutaneous injection of 0.5 mL at 0, 2, 4, and 6 months
0.5 mL subcutaneously given as part of a booster series six and twelve months after the initial series and then every twelve months after that
Post-Exposure Prophylaxis: First series: 0.5 mL subcutaneous injection given in conjunction with antimicrobial therapy at 0, 2, and 4 weeks after exposure
indications: it is indicated inanthrax immunization
may increase the risk of toxic effects when combined
may diminish the therapeutic efficacy when combination
may diminish the activity of each other
the activity of the anthrax vaccine can be reduced when used in combination with abacavir
the activity of the anthrax vaccine can be reduced when used in combination with acyclovir
the risk of adverse effects can be enhanced when adalimumab is administered with anthrax vaccine adsorbed
the activity of the anthrax vaccine can be reduced when used in combination with aldesleukin
the activity of the anthrax vaccine can be reduced when used in combination with anakinra
the activity of the anthrax vaccine can be reduced when used in combination with amprenavir
the activity of the anthrax vaccine can be reduced when used in combination with betamethasone
the activity of the anthrax vaccine can be reduced when used in combination with bexarotene
the activity of the anthrax vaccine can be reduced when used in combination with bleomycin
the activity of the anthrax vaccine can be reduced when used in combination with chlorambucil
the activity of the anthrax vaccine can be reduced when used in combination with corticotropin
the activity of the anthrax vaccine can be reduced when used in combination with dacarbazine
the activity of the anthrax vaccine can be reduced when used in combination with dasatinib
the activity of the anthrax vaccine can be reduced when used in combination with denosumab
the activity of the anthrax vaccine can be reduced when used in combination with didanosine
the activity of the anthrax vaccine can be reduced when used in combination with doravirine
the activity of the anthrax vaccine can be reduced when used in combination with efalizumab
the activity of the anthrax vaccine can be reduced when used in combination with grazoprevir
the activity of the anthrax vaccine can be reduced when used in combination with voclosporin
the activity of the anthrax vaccine can be reduced when used in combination with zidovudine
when both drugs combine the toxicity of anthrax vaccine adsorbed decreases by melphalan.
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of infection   
when both drugs are combined, there may be a reduced response to the vaccine   
the therapeutic activity of anthrax vaccine may be reduced